Ascletis Pharma Inc. (HKG:1672)

Ascletis Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,580	865.73	330.12	403.77	2,495	2,714
Short-Term Investments	199.9	1,079	1,948	2,070	2.59	2.21
Trading Asset Securities	20.7	7.37	24.83	11.2	5.2	-
Cash & Short-Term Investments	1,801	1,953	2,303	2,485	2,503	2,716
Cash Growth	-13.94%	-15.23%	-7.30%	-0.74%	-7.84%	-9.28%
Accounts Receivable	0.41	0.15	5.43	23.87	53.61	26.62
Other Receivables	14.93	9.11	12.85	5.4	13.79	21.61
Receivables	15.34	9.26	18.28	29.27	67.39	48.23
Inventory	4.82	4.37	6.07	20.52	56.23	58.89
Prepaid Expenses	0.9	1.01	1.03	2.13	2.3	1.85
Other Current Assets	0.94	3.62	4.13	8.13	2.34	4.8
Total Current Assets	1,823	1,971	2,333	2,545	2,632	2,830
Property, Plant & Equipment	51.99	57.07	68.28	71.83	77.51	84.58
Long-Term Investments	110.65	84.39	63.02	22.02	41.86	60.92
Other Intangible Assets	10.92	12.12	26.32	16.56	78.21	90.7
Long-Term Deferred Charges	0.35	0.08	0.38	0.7	0.42	0.89
Other Long-Term Assets	-	0.13	0.26	1.22	0.41	-
Total Assets	1,997	2,125	2,491	2,657	2,830	3,067
Accounts Payable	0.02	0.03	0.65	3.14	1.05	0.93
Accrued Expenses	77.23	83.8	91.87	56.15	52.29	31.74
Current Portion of Leases	3.57	6.25	5.71	2.42	1.57	1.14
Current Unearned Revenue	1.98	1.98	1.59	1.97	1.59	1.72
Other Current Liabilities	42.33	61	40.86	44.52	34.47	38.23
Total Current Liabilities	125.13	153.05	140.68	108.19	90.97	73.77
Long-Term Leases	0.7	1.39	2.71	1.82	1.18	0.44
Long-Term Unearned Revenue	3.18	3.97	5.56	7.15	8.73	11.21
Total Liabilities	129	158.41	148.94	117.16	100.89	85.42
Common Stock	0.66	0.69	0.73	0.74	0.75	0.75
Additional Paid-In Capital	2,704	2,750	2,843	2,867	2,884	2,898
Retained Earnings	-1,563	-1,475	-1,174	-1,030	-714.85	-515.83
Treasury Stock	-16.23	-56.7	-51.95	-	-18.71	-4.52
Comprehensive Income & Other	742.38	747.55	724.56	702	578.32	603.19
Total Common Equity	1,868	1,966	2,342	2,540	2,729	2,982
Shareholders' Equity	1,868	1,966	2,342	2,540	2,729	2,982
Total Liabilities & Equity	1,997	2,125	2,491	2,657	2,830	3,067
Total Debt	4.27	7.63	8.42	4.24	2.75	1.59
Net Cash (Debt)	1,797	1,945	2,295	2,480	2,501	2,715
Net Cash Growth	-13.78%	-15.25%	-7.48%	-0.80%	-7.89%	-9.21%
Net Cash Per Share	1.84	1.94	2.14	2.28	2.28	2.61
Filing Date Shares Outstanding	963.65	971.07	1,061	1,087	1,096	1,101
Total Common Shares Outstanding	963.65	971.07	1,061	1,087	1,096	1,101
Working Capital	1,698	1,818	2,192	2,437	2,541	2,756
Book Value Per Share	1.94	2.02	2.21	2.34	2.49	2.71
Tangible Book Value	1,857	1,954	2,316	2,523	2,651	2,891
Tangible Book Value Per Share	1.93	2.01	2.18	2.32	2.42	2.63
Machinery	-	127.38	126.13	121.54	115.33	110.82
Construction In Progress	-	-	-	-	0.03	-
Leasehold Improvements	-	2.87	2.87	2.87	2.87	2.87

Source: S&P Global Market Intelligence. Standard template. Financial Sources.